Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | SCLC | Research

Construction and validation of a nomogram to predict the overall survival of small cell lung cancer: a multicenter retrospective study in Shandong province, China

Authors: Ziqian Song, Hengmin Ma, Hao Sun, Qiuxia Li, Yan Liu, Jing Xie, Yukun Feng, Yuwang Shang, Kena Ma, Nan Zhang, Jialin Wang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Patients diagnosed with small cell lung cancer (SCLC) typically experience a poor prognosis, and it is essential to predict overall survival (OS) and stratify patients based on distinct prognostic risks.

Methods

Totally 2309 SCLC patients from the hospitals in 15 cities of Shandong from 2010 − 2014 were included in this multicenter, population-based retrospective study. The data of SCLC patients during 2010–2013 and in 2014 SCLC were used for model development and validation, respectively. OS served as the primary outcome. Univariate and multivariate Cox regression were applied to identify the independent prognostic factors of SCLC, and a prognostic model was developed based on these factors. The discrimination and calibration of this model were assessed by the time-dependent C-index, time-dependent receiver operator characteristic curves (ROC), and calibration curves. Additionally, Decision Curve Analysis (DCA) curves, Net Reclassification Improvement (NRI), and Integrated Discriminant Improvement (IDI) were used to assess the enhanced clinical utility and predictive accuracy of the model compared to TNM staging systems.

Results

Multivariate analysis showed that region (Southern/Eastern, hazard ratio [HR] = 1.305 [1.046 − 1.629]; Western/Eastern, HR = 0.727 [0.617 − 0.856]; Northern/Eastern, HR = 0.927 [0.800 − 1.074]), sex (female/male, HR = 0.838 [0.737 − 0.952]), age (46–60/≤45, HR = 1.401 [1.104 − 1.778]; 61–75/≤45, HR = 1.500 [1.182 − 1.902]; >75/≤45, HR = 1.869 [1.382 − 2.523]), TNM stage (II/I, HR = 1.119[0.800 − 1.565]; III/I, HR = 1.478 [1.100 − 1.985]; IV/I, HR = 1.986 [1.477 − 2.670], surgery (yes/no, HR = 0.677 [0.521 − 0.881]), chemotherapy (yes/no, HR = 0.708 [0.616 − 0.813]), and radiotherapy (yes/no, HR = 0.802 [0.702 − 0.917]) were independent prognostic factors of SCLC patients and were included in the nomogram. The time-dependent AUCs of this model in the training set were 0.699, 0.683, and 0.683 for predicting 1-, 3-, and 5-year OS, and 0.698, 0.698, and 0.639 in the validation set, respectively. The predicted calibration curves aligned with the ideal curves, and the DCA curves, the IDI, and the NRI collectively demonstrated that the prognostic model had a superior net benefit than the TNM staging system.

Conclusion

The nomogram using SCLC patients in Shandong surpassed the TNM staging system in survival prediction accuracy and enabled the stratification of patients with distinct prognostic risks based on nomogram scores.
Appendix
Available only for authorised users
Literature
1.
18.
go back to reference Camp RL, Dolled-Filhart M, Rimm DL, X-Tile. A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization[J]. Camp RL, Dolled-Filhart M, Rimm DL, X-Tile. A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization[J].
29.
go back to reference Yang Y, Sun S, Wang Y et al. Development and validation of nomograms for predicting survival of elderly patients with stage I small-cell Lung cancer[J/OL]. Bosnian J Basic Med Sci, 2021[2022-11-25]. Yang Y, Sun S, Wang Y et al. Development and validation of nomograms for predicting survival of elderly patients with stage I small-cell Lung cancer[J/OL]. Bosnian J Basic Med Sci, 2021[2022-11-25].
Metadata
Title
Construction and validation of a nomogram to predict the overall survival of small cell lung cancer: a multicenter retrospective study in Shandong province, China
Authors
Ziqian Song
Hengmin Ma
Hao Sun
Qiuxia Li
Yan Liu
Jing Xie
Yukun Feng
Yuwang Shang
Kena Ma
Nan Zhang
Jialin Wang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11692-7

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine